1139PSensitizing HRAS overexpressing head and neck squamous cell carcinoma (HNSCC) to chemotherapy
ConclusionsERCC1 expression is a well-established biomarker for cisplatin resistance. Our study demonstrates that wtHRASov tumours represent a distinctive entity that strongly express ERCC1 and can be resensitized to cisplatin by tipifarnib.Legal entity responsible for the studyThe authors.FundingKura Oncology.DisclosureT. Rampias: Research grant / Funding (institution): Kura Oncology Company. All other authors have declared no conflicts of interest.
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research
More News: Cancer | Cancer & Oncology | Carcinoma | Chemotherapy | Gastroschisis Repair | Grants | Head and Neck Cancer | HNSCC | Legislation | Skin Cancer | Squamous Cell Carcinoma | Study